Overall market sentiment has been high on Kalvista Pharmaceuticals Inc (KALV) stock lately. KALV receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.
Kalvista Pharmaceuticals Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on KALV!
In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With KALV Stock Today?
Kalvista Pharmaceuticals Inc (KALV) stock is down -0.4% while the S&P 500 is higher by 1% as of 12:04 PM on Friday, Nov 3. KALV is lower by -$0.03 from the previous closing price of $8.66 on volume of 27,746 shares. Over the past year the S&P 500 has gained 16.00% while KALV is higher by 62.83%. KALV lost -$3.16 per share in the over the last 12 months.
To screen for more stocks like Kalvista Pharmaceuticals Inc click here.
More About Kalvista Pharmaceuticals Inc
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States.
Click Here to get the full Stock Report for Kalvista Pharmaceuticals Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
